Source disclosure: February 13, 2026
OLYMPUS CORPORATION [7733.T]
TOKYO, Feb 13 (Pulse News Wire) – Olympus Corporation (7733.T) reported strong growth in its fiscal 2026 third quarter earnings, driven by robust performance in Europe, emerging markets, and China. However, the company faced challenges due to U.S.
Tariffs and product shipment holds, leading to a decline in adjusted operating income. Sales grew significantly, benefiting from favorable exchange rates. In the gastrointestinal endoscopy solutions sector, sales increased despite delays in North America, while Europe and parts of Asia-Pacific showed solid progress. New products such as the EU-ME3 ultrasound probe and locally produced upper GI EDOF scope contributed to the growth.
Adjusted operating profit was revised to a range of 12.7% to 13.9% percent, reflecting ongoing cost management efforts. CEO Bob White emphasized maintaining commitment to long-term structural reforms aimed at reducing costs by approximately ¥240 billion annually from fiscal years 2027 through 2029. For the full fiscal year ending March 2026, Olympus forecasted revenue to remain stable compared to previous estimates but anticipated lower gross margins due to ongoing shipment issues in surgical intervention products. The company also projected higher expenses related to strategic investments and restructuring initiatives.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing